A 52-year-old woman with a history of chronic kidney disease undergoes ultrasound for hypertension workup. A 2.5 cm hyperechoic mass is incidentally found in the left kidney. Ultrasound cannot definitively characterise it as benign or malignant. What is the most appropriate next investigation?

Explanation

## Characterisation of Indeterminate Renal Mass **Key Point:** When ultrasound cannot definitively characterise a renal mass as benign or malignant, **contrast-enhanced CT (CECT)** is the next best investigation because it reliably distinguishes solid tumours from cysts and characterises enhancement patterns. ### Diagnostic Algorithm for Indeterminate Renal Mass ```mermaid flowchart TD A[Renal mass on ultrasound]:::outcome --> B{Clearly benign cyst?}:::decision B -->|Yes: simple cyst| C[No further imaging]:::action B -->|No: indeterminate| D[CECT abdomen/pelvis]:::action D --> E{Enhancement pattern?}:::decision E -->|No enhancement| F[Benign: likely oncocytoma/AML]:::outcome E -->|Arterial enhancement| G[Suspicious for RCC]:::urgent G --> H[Staging CECT + biopsy if needed]:::action E -->|Minimal enhancement| I[Likely benign: follow-up imaging]:::action ``` ### Why CECT is Superior for Characterisation | Feature | CECT | Renal Biopsy | MRI (no gadolinium) | Follow-up US | |---------|------|--------------|---------------------|---------------| | **Characterises mass** | Excellent (enhancement pattern) | Tissue diagnosis but invasive | Limited without contrast | Limited | | **Detects enhancement** | Yes (arterial, venous, delayed) | N/A | No (no gadolinium) | No | | **Distinguishes RCC from benign** | 95% sensitivity | 100% but invasive | Poor without contrast | Unreliable | | **Risk of complications** | Contrast reaction, nephropathy | Bleeding, infection, seeding | None | Delayed diagnosis | | **Cost-effective** | Yes | Expensive, invasive | Expensive | Delays diagnosis | **High-Yield:** CECT enhancement patterns in renal masses: - **RCC:** Arterial phase enhancement (>20 HU increase), washout in delayed phase - **Oncocytoma:** Homogeneous enhancement, central scar (benign) - **Angiomyolipoma (AML):** Fat density (−10 to −100 HU) on unenhanced CT — diagnostic - **Simple cyst:** No enhancement, water density (0–20 HU) - **Bosniak classification:** Grades cystic lesions I–IV; III/IV require follow-up or intervention ### Why Other Options Are Incorrect **Renal biopsy:** - Invasive with risk of **bleeding, infection, and tumour seeding** - Reserved for: - Confirmation of diagnosis when imaging is equivocal AND management depends on it - Suspected metastatic disease to kidney - Evaluation of renal dysfunction (not applicable here) - NOT first-line for characterising an indeterminate mass **MRI without gadolinium:** - Gadolinium is essential for characterising renal masses (contrast-enhanced MRI = CEMRI) - Non-contrast MRI provides no enhancement information and cannot reliably distinguish RCC from benign lesions - Delays diagnosis unnecessarily **Follow-up ultrasound in 3 months:** - Ultrasound has poor specificity for characterising solid renal masses - Delays diagnosis of potentially malignant lesion - If mass is RCC, delay increases stage and reduces survival - Only appropriate for **clearly benign** cysts (Bosniak I) or in patients with contraindications to contrast **Clinical Pearl:** A **2.5 cm hyperechoic mass** on ultrasound is suspicious for RCC (clear cell carcinoma often appears hyperechoic due to lipid content) or benign lesions (oncocytoma, AML). CECT will definitively characterise it: - If it enhances in arterial phase → likely RCC → proceed to staging and surgery - If it shows fat density → AML (benign) → conservative management - If it shows no enhancement → likely oncocytoma → follow-up imaging **Mnemonic: CECT for indeterminate mass** = **C**haracterise, **E**nhancement pattern, **C**onfirm diagnosis, **T**reatment planning.